An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.

BACKGROUND:The transmembrane receptor tyrosine kinase HER2 is overexpressed in approximately 15% of breast tumors and correlates with poor clinical prognosis. Several treatments that target HER2 are approved for treatment of HER2-positive metastatic breast cancer. The serum biomarkers most widely us...

Full description

Bibliographic Details
Main Authors: Alexandre Perrier, Pierre-Yves Boelle, Yves Chrétien, Joseph Gligorov, Jean-Pierre Lotz, Didier Brault, Eva Comperat, Guillaume Lefèvre, Mathieu Boissan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0227356

Internet

https://doi.org/10.1371/journal.pone.0227356

Similar Items